(196 days)
Not Found
No
The description details a manual, mechanical stapling device with no mention of computational or learning capabilities.
No.
The stapler is used to create anastomoses by joining tissues together, which is a surgical procedure rather than a therapeutic treatment for a disease or condition.
No
The device is a surgical stapler used for creating anastomoses, which is a therapeutic function, not a diagnostic one.
No
The device description clearly outlines a physical, manual surgical stapler made of materials like stainless steel and titanium, which is activated by squeezing a handle. It is a hardware device used in surgical procedures.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for creating anastomoses (surgical connections) within the alimentary tract during open and laparoscopic surgeries. This is a surgical procedure performed directly on the patient's body.
- Device Description: The device is a surgical stapler that physically manipulates and staples tissue. It does not involve testing samples of bodily fluids or tissues outside of the body to diagnose a condition or provide information about a physiological state.
- Lack of IVD Characteristics: The description does not mention any components or functions related to analyzing biological samples, detecting analytes, or providing diagnostic information.
IVD devices are specifically designed to be used in vitro (outside the body) to examine specimens from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device is used in vivo (inside the body) for a surgical procedure.
N/A
Intended Use / Indications for Use
The EEA™ Circular Stapler with Tri-Staple™ Technology has application throughout the alimentary tract for the creation of end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.
Product codes (comma separated list FDA assigned to the subject device)
GDW
Device Description
The EEA™ circular stapler with Tri-Staple™ technology places a circular, triple staggered row of titanium staples and resects the excess tissue, creating a circular anastomosis. The instrument is activated by squeezing the handle firmly as far as it will go. The diameter of the staple line is 33 mm, 31 mm, 28 mm. The EEA™ circular stapler with Tri-Staple™ technology is available in 2 shaft lengths; a standard 22 cm shaft and an XL 35 cm shaft. The staplers are offered in one staple size medium/thick. Staplers with medium/thick staple size (purple) deploy three height progressive rows of 3.0 mm, 3.5 mm and 4.0 mm titanium staples. The low profile Tilt-Top™ anvil is available on all staplers. A blunt tipped anvil trocar accessory is provided to assist in introducing the anvil into the surgical field.
The EEA™ Circular Stapler with Tri-Staple™ Technology places a circular, triple staggered row of titanium staples and resects the excess tissue, creating a circular anastomosis as an end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.
The EEA™ Circular Stapler with Tri-Staple™ Technology is a manual single-use device that is packaged and sterilized via ETO (Ethylene Oxide) with a 5-year shelf life.
The EEA™ Circular Stapler with Tri-Staple™ Technology is manufactured with patient contact materials (stainless Steel, titanium) that are utilized within the predicate device (K062850).
The EEA™ Circular Stapler with Tri-Staple™ Technology is utilized by approximating tissue, instrumentation activation by squeezing the handle firmly as far as it will go, audible and tactile firing indicator upon completion of the staple firing and removal of the device from the surgical field in the same manner as the predicate device (K062850).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Alimentary tract
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation activities were successfully completed. Evidence of safety and effectiveness in support of substantial equivalence were obtained from design verification and validation testing. The design differences were found to not affect safety or performance through applicable design verification activities that demonstrated conformance to applicable technical design specifications and performance requirements, applicable medical device performance standards and other nonclinical testing.
Tests performed to evaluate and compare technological and performance characteristics:
-
- Stability Testing
- Accelerated aging test for 5 years shelf life
-
- Sterilization validation per ISO 11135-1 and ISO 10993-7
- Overkill method used for validation
- ETO Residuals
-
- Biocompatibility testing in accordance to ISO 10993-1 and FDA guidance "Use of International Standard ISO 10993-1" issued June 16, 2016
- Neutral Red Uptake (NRU) Cytotoxicity test
- ISO Guinea Pig Maximization Sensitization
- ISO Intracutaneous Irritation
- ISO Acute system toxicity
- Pyrogenicity
-
- Performance Test In Vitro
- Staple formation
- Anvil attach force
- Anvil detach force
- Firing force
-
- Performance Test In Vivo
- External Atraumatic tissue
- Hemostasis
- Staple formation
- Knife cut
- Anastomotic burst pressure
- Non-Clinical Chronic Study - Assessment of colo-colonic and gastro-jejunal anastomoses
-
- Performance Test Human Factors / Usability
- Device performance evaluation per design specifications
- Validate potential use error per Risk and Hazard analysis
- Validate training and Instructions for Use
The performance testing including In-Vivo and Human Factors/Usability were all conducted on both the subject and predicate devices. The evaluation testing concludes that the EEA™ circular stapler with Tri-Staple™ Technology was found to be substantially equivalent to the predicate device in terms of clinical performance and does not raise new questions of safety and effectiveness.
This premarket submission did not rely on the assessment of clinical performance data to demonstrate substantial equivalence. This submission does not include data from clinical studies.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4750 Implantable staple.
(a)
Identification. An implantable staple is a staple-like device intended to connect internal tissues to aid healing. It is not absorbable.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and consists of the letters "FDA" stacked above the words "U.S. FOOD & DRUG" and "ADMINISTRATION".
February 16, 2018
Covidien Sarah Tang Sr. Regulatory Affair Specialist Rooms 501, 502, 601, 602 No.3 building No.2388. Chen Hang Road Min Hang District, Shanghai, 201114 Cn
Re: K172361
Trade/Device Name: EEA Circular Stapler with Tri-Staple Technology Regulation Number: 21 CFR 878.4750 Regulation Name: Implantable Staple Regulatory Class: Class II Product Code: GDW Dated: August 2, 2017 Received: August 4, 2017
Dear Sarah Tang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
David Krause -S
for Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.
510(k) Number (if known)
Device Name
EEATM Circular Stapler with Tri-Staple™ Technology
Indications for Use (Describe)
The EEA™ Circular Stapler with Tri-Staple™ Technology has application throughout the alimentary tract for the creation of end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (7/17)
Page 1 of 1
PSC Publishing Services (301) 443-4740 EF
3
510(k) Summary per 21 CFR 807.92
Date Prepared:
February 14, 2018
Submitter:
Sarah Tang Covidien Rooms 501, 502, 601, 602, No. 3 Building No .: 2388 Chen Hang Road Min Hang District, Shanghai 201114 China
Contact:
Frank Gianelli (U.S. Agent) on behalf of Sarah Tang Senior Regulatory Affairs Specialist 60 Middletown Avenue North Haven, CT 06473 U.S.A Office 203.492.5352 | Fax 203.492.5029 | Email frank.gjanelli@medtronic.com
Name of Device:
Trade/Proprietary Name: EEA™ Circular Stapler with Tri-Staple™ Technology Model Numbers: TRIEEA28MT, TRIEEA31MT, TRIEEAXL33MT Classification Name: Surgical Stapler with Implantable Staples Classification (21 CFR 878.4750) Regulation Name: Implantable Staple Panel Number: 79
Product Code: GDW, Class: II
Predicate Device:
Trade/Proprietary Name: EEA™ Circular Stapler with DST Series™ Technology Common Name: Surgical Stapler with Implantable Staples Classification Product Code, Regulation: GDW, 21 CFR 878.4750 / GAG, 21 CFR 878.4800 510(k) Number: K062850 Class: Il Manufacturer: Covidien
Device Description:
The EEA™ circular stapler with Tri-Staple™ technology places a circular, triple staggered row of titanium staples and resects the excess tissue, creating a circular anastomosis. The instrument is activated by squeezing the handle firmly as far as it will go. The diameter of the staple line is 33 mm, 31 mm, 28 mm. The EEA™ circular stapler with Tri-Staple™ technology is available in 2 shaft lengths; a standard 22 cm shaft and an XL 35 cm shaft. The staplers are offered in one staple size medium/thick. Staplers with medium/thick staple size (purple) deploy three height progressive rows of 3.0 mm, 3.5 mm and 4.0 mm titanium staples. The low profile Tilt-Top™ anvil is available on all staplers. A blunt tipped anvil trocar accessory is provided to assist in introducing the anvil into the surgical field.
4
The EEA™ Circular Stapler with Tri-Staple™ Technology places a circular, triple staggered row of titanium staples and resects the excess tissue, creating a circular anastomosis as an end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.
The EEA™ Circular Stapler with Tri-Staple™ Technology is a manual single-use device that is packaged and sterilized via ETO (Ethylene Oxide) with a 5-year shelf life.
The EEA™ Circular Stapler with Tri-Staple™ Technology is designed for prescription use only per 21 CFR 801 Subpart D. The device is utilized in open and laparoscopic surgical procedures.
The EEA™ Circular Stapler with Tri-Staple™ Technology is manufactured with patient contact materials (stainless Steel, titanium) that are utilized within the predicate device (K062850).
The EEA™ Circular Stapler with Tri-Staple™ Technology is utilized by approximating tissue, instrumentation activation by squeezing the handle firmly as far as it will go, audible and tactile firing indicator upon completion of the staple firing and removal of the device from the surgical field in the same manner as the predicate device (K062850).
Indications for Use:
The EEA™ circular stapler with Tri-Staple™ technology has application throughout the alimentary tract for the creation of end-to-end, end-to-side and side-to-side anastomoses in both open and laparoscopic surgeries.
Technological and Performance Characteristics:
The EEA™ circular stapler with Tri-Staple™ technology is substantially equivalent to the predicate EEA™ Circular Stapler with DST Series™ Technology in regard to the fundamental stapling technologies employed. The proposed device EEA™ Circular Stapler with Tri-Staple™ Technology places a circular, triple staggered row of titanium staples and resects the tissue, creating a circular anastomosis.
The EEA™ circular stapler with Tri-Staple™ technology and predicate EEA™ Circular Stapler with DST Series™ Technology (K062850) are designed to approximate, cut and staple tissue for the purpose of creating anastomoses.
Basis for the Substantial Equivalence:
The EEA™ circular stapler with Tri-Staple™ technology has the same intended use as the identified predicate device.
They are similar in fundamental scientific technology in that they are all sterile, hand-held, manual surgical instruments equipped with titanium staples intended to be used during open or laparoscopic surgical procedures of the alimentary tract, to create anastomoses (end-to-end, endto-side, or side-to-side) via intraluminal (within the lumen) resection. The proposed and predicate devices are similar in design, materials and are sterilized via ethylene oxide.
5
| Proposed Device | Predicate Device (K062850) | |
|---|---|---|
| EEA™ Circular Stapler with Tri-Staple™ | EEA™ Circular Stapler with DST Series™ | |
| Technology | Technology | |
| Manufacturer | Covidien | Covidien |
| Constructional | Image: Circular Stapler with Tri-Staple Technology | Image: Circular Stapler with DST Series Technology |
| Indications for Use | The EEA™ Circular Stapler with Tri-Staple™ | |
| Technology has application throughout the | ||
| alimentary tract for the creation of end-to-end, | ||
| end-to-side and side-to-side anastomoses in both | ||
| open and laparoscopic surgeries. | The EEA™ Circular Stapler with DST™ Staple | |
| Technology has application throughout the | ||
| alimentary tract for the creation of end-to-end, end- | ||
| to-side and side-to-side anastomoses in both open | ||
| and laparoscopic surgeries, including bariatric | ||
| surgery. | ||
| Operation Method | Manual | Manual |
| Anatomical Site | Alimentary tract | Alimentary tract |
| Surgical Approach | Open and laparoscopic | Open and laparoscopic |
| Staple Rows | 3 staggered rows of staples with different staple | |
| height in each staple row | 2 staggered rows of staples with same staple | |
| height in each staple row | ||
| Staple Height | 3.0mm, 3.5mm, 4.0mm | 3.5mm |
| 4.8mm | ||
| Shell Diameter | 28mm/31mm/33mm | 21mm/25mm/28mm/31mm/33mm |
| Stapler Length | Standard length: 22cm | |
| Extra length XL: 35cm | Standard length: 22cm | |
| Extra length XL: 35cm | ||
| Audible Feedback | Yes | Yes |
| Anvil Head | 3 staggered rows of anvil bucket. Lipless design | 2 staggered rows of anvil bucket, Lipped design |
| Safety Lever | Red color | White color |
| Patient Contact | ||
| Material(s) | Staple (implant): Titanium per ASTM F67 Grade 1 | |
| Knife: 440 Stainless Steel | ||
| Anvil: 17-4 Stainless Steel | ||
| Tube: Aluminum 6061 T-6 | Staple (Implant): Titanium per ASTM F67 Grade 1 | |
| Knife: 440 Stainless Steel | ||
| Anvil: 17-4 Stainless Steel | ||
| Tube: Aluminum 6061 T-6 | ||
| Biocompatibility | Yes, per ISO 10993-1 | Yes, per ISO 10993-1 |
| Single Use | Yes | Yes |
| Sterile | Ethylene oxide | Ethylene oxide |
| Shelf Life | 5 years | 5 years |
Verification and validation activities were successfully completed. Evidence of safety and effectiveness in support of substantial equivalence were obtained from design verification and validation testing. The design differences were found to not affect safety or performance through applicable design verification activities that demonstrated conformance to applicable technical design specifications and performance requirements, applicable medical device performance standards and other nonclinical testing.
Tests performed to evaluate and compare technological and performance characteristics:
-
- Stability Testing
- Accelerated aging test for 5 years shelf life o
-
- Sterilization validation per ISO 11135-1 and ISO 10993-7
- Overkill method used for validation o
- o ETO Residuals
6
-
- Biocompatibility testing in accordance to ISO 10993-1 and FDA guidance "Use of International Standard ISO 10993-1" issued June 16, 2016
- Neutral Red Uptake (NRU) Cytotoxicity test 0
- ISO Guinea Pig Maximization Sensitization 0
- 0 ISO Intracutaneous Irritation
- ISO Acute system toxicity 0
- 0 Pyrogenicity
-
- Performance Test In Vitro
- 0 Staple formation
- Anvil attach force 0
- Anvil detach force 0
- 0 Firing force
-
- Performance Test In Vivo
- 0 External Atraumatic tissue
- 0 Hemostasis
- 0 Staple formation
- Knife cut 0
- O Anastomotic burst pressure
- 0 Non-Clinical Chronic Study - Assessment of colo-colonic and gastro-jejunal anastomoses
-
- Performance Test Human Factors / Usability
- Device performance evaluation per design specifications 0
- 0 Validate potential use error per Risk and Hazard analysis
- 0 Validate training and Instructions for Use
This premarket submission did not rely on the assessment of clinical performance data to demonstrate substantial equivalence.
Conclusion:
The performance testing including In-Vivo and Human Factors/Usability were all conducted on both the subject and predicate devices. The evaluation testing concludes that the EEA™ circular stapler with Tri-Staple™ Technology was found to be substantially equivalent to the predicate device in terms of clinical performance and does not raise new questions of safety and effectiveness.
This submission does not include data from clinical studies.